RY 139.89 0.8943% TD 76.9 1.2242% SHOP 86.16 -18.5248% CNR 172.89 0.5818% ENB 51.15 1.1269% CP 112.14 0.5199% BMO 127.56 0.9816% TRI 229.43 0.1528% CNQ 105.96 1.0105% BN 60.44 0.683% ATD 75.02 0.4015% CSU 3820.47 1.7341% BNS 65.64 1.4685% CM 66.73 1.3364% SU 53.67 0.4304% TRP 52.0 1.069% NGT 57.07 0.3693% WCN 227.19 0.0528% MFC 33.6 0.9919% BCE 46.16 0.5445%
Last update at 2024-05-08T20:00:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 22.20M | 22.27M | 10.15M | 11.94M | 10.22M |
Minority interest | - | - | - | -0.08900M | -0.08900M |
Net income | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
Selling general administrative | 36.11M | 26.32M | 18.32M | 11.58M | 15.51M |
Selling and marketing expenses | 67.12M | 54.29M | 34.13M | 14.02M | - |
Gross profit | 126.16M | 102.98M | 62.70M | 36.66M | 25.88M |
Reconciled depreciation | 3.13M | 2.29M | 1.57M | 0.78M | 0.45M |
Ebit | 19.81M | 20.08M | 10.25M | 10.29M | 9.92M |
Ebitda | 22.94M | 22.37M | 11.74M | 11.07M | 10.37M |
Depreciation and amortization | 3.13M | 2.29M | 1.50M | 0.78M | 0.45M |
Non operating income net other | -0.30000M | - | -0.07700M | 0.88M | - |
Operating income | 22.94M | 22.37M | 10.25M | 11.07M | 10.37M |
Other operating expenses | 135.23M | 107.94M | 69.87M | 34.41M | 21.55M |
Interest expense | 0.44M | 0.10M | 0.02M | 0.00500M | 0.15M |
Tax provision | 5.15M | 5.17M | 1.08M | 2.45M | 0.66M |
Interest income | - | - | - | 0.00500M | 0.15M |
Net interest income | -0.44000M | -0.09500M | -0.01900M | -0.00500M | -0.15400M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 5.15M | 5.17M | 1.08M | 2.45M | 0.66M |
Total revenue | 158.17M | 130.30M | 80.12M | 45.47M | 31.92M |
Total operating expenses | 103.22M | 80.61M | 52.46M | 25.59M | 15.51M |
Cost of revenue | 32.01M | 27.32M | 17.42M | 8.81M | 6.04M |
Total other income expense net | -0.74000M | -0.09500M | -0.09600M | 0.88M | -0.15400M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
Net income applicable to common shares | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 116.47M | 133.27M | 72.17M | 28.28M | 16.18M |
Intangible assets | 9.07M | 9.97M | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 0.87M | 0.69M | 1.38M | 0.32M | 0.57M |
Total liab | 50.11M | 59.35M | 15.32M | 8.62M | 6.89M |
Total stockholder equity | 66.36M | 73.92M | 56.85M | 19.74M | 9.39M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 5.99M | 9.82M | 3.27M | 1.81M | 4.80M |
Common stock | 0.04M | 0.04M | 0.04M | 0.03M | 0.03M |
Capital stock | 0.04M | 0.04M | 0.04M | 0.03M | 0.03M |
Retained earnings | 17.05M | 0.00000M | 23.43M | 14.36M | 4.87M |
Other liab | 10.00M | 9.70M | - | - | 0.53M |
Good will | 20.40M | 20.40M | - | - | - |
Other assets | 2.15M | 1.30M | 0.91M | 0.84M | 1.04M |
Cash | 20.14M | 42.61M | 39.17M | 14.04M | 10.13M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 21.09M | 22.87M | 10.12M | 5.20M | 6.36M |
Current deferred revenue | 1.56M | - | - | - | - |
Net debt | 6.82M | -7.52400M | -31.84200M | -9.35700M | -10.12800M |
Short term debt | 7.94M | 8.31M | 2.13M | 1.26M | - |
Short long term debt | 5.33M | 5.33M | - | - | - |
Short long term debt total | 26.96M | 35.09M | 7.33M | 4.68M | - |
Other stockholder equity | 49.27M | 73.88M | 33.39M | 5.35M | 4.48M |
Property plant equipment | 2.17M | 18.91M | 1.93M | 4.87M | 3.89M |
Total current assets | 69.56M | 82.69M | 63.02M | 22.57M | 14.33M |
Long term investments | - | - | - | - | - |
Net tangible assets | 36.89M | 43.55M | 56.85M | 19.74M | 9.38M |
Short term investments | - | - | - | - | - |
Net receivables | 35.06M | 28.63M | 13.84M | 5.83M | 2.79M |
Long term debt | 5.29M | 10.61M | - | - | - |
Inventory | 13.48M | 10.76M | 8.63M | 2.38M | 0.84M |
Accounts payable | 5.60M | 4.74M | 4.72M | 2.13M | 1.55M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | -0.08900M | -0.08900M |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | - | -2.06300M | -1.46200M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | 0.04M | 0.04M | 0.04M | 0.03M | 0.03M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | 17.05M | - | 23.43M | 14.36M | 4.87M |
Treasury stock | - | -6.51300M | -3.84600M | -3.84600M | -3.67500M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 0.86M | 0.97M | 0.67M | 0.51M | 0.31M |
Deferred long term asset charges | - | - | - | - | 0.72M |
Non current assets total | 46.91M | 50.59M | 9.15M | 5.71M | 1.86M |
Capital lease obligations | 16.33M | 19.15M | 7.33M | 4.68M | 0.00000M |
Long term debt total | 5.29M | 10.61M | - | 0.14M | 0.01000M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -0.41800M | -16.60600M | -0.98500M | -0.16000M | -1.08200M |
Change to liabilities | 1.83M | 2.89M | 3.77M | 0.79M | 0.35M |
Total cashflows from investing activities | -0.41800M | -16.60600M | -0.98500M | -0.16000M | -1.08200M |
Net borrowings | -5.33300M | 15.95M | -0.05700M | -0.01900M | -0.50700M |
Total cash from financing activities | -35.79600M | 13.10M | 25.30M | -2.23100M | -3.76300M |
Change to operating activities | -0.18600M | 0.45M | -0.66500M | 0.31M | 0.06M |
Net income | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
Change in cash | -22.46800M | 3.44M | 25.13M | 3.91M | 4.56M |
Begin period cash flow | 42.61M | 39.17M | 14.04M | 10.13M | 5.57M |
End period cash flow | 20.14M | 42.61M | 39.17M | 14.04M | 10.13M |
Total cash from operating activities | 13.75M | 6.95M | 0.82M | 6.30M | 9.41M |
Issuance of capital stock | - | 0.00000M | 25.20M | 0.22M | 0.18M |
Depreciation | 3.13M | 2.29M | 1.57M | 0.78M | 0.45M |
Other cashflows from investing activities | - | -15.99700M | - | - | - |
Dividends paid | 3.61M | 0.00100M | 0.00100M | 2.26M | 2.27M |
Change to inventory | -4.32000M | -3.77600M | -7.32300M | -2.36000M | -0.41400M |
Change to account receivables | -6.43000M | -14.78100M | -8.00400M | -3.04200M | -0.60600M |
Sale purchase of stock | -26.42600M | -2.66700M | 25.77M | -0.17100M | -3.43200M |
Other cashflows from financing activities | -0.35200M | -0.25200M | 0.15M | -0.16000M | -1.08200M |
Change to netincome | 1.79M | 1.48M | 2.63M | 1.22M | -0.35200M |
Capital expenditures | 0.42M | 0.61M | 0.98M | 0.16M | 1.08M |
Change receivables | -6.43000M | -14.78100M | -8.00400M | -3.04200M | -0.60600M |
Cash flows other operating | 0.70M | 1.74M | -0.90100M | -0.56700M | 0.27M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | -22.46800M | 3.44M | 25.13M | 3.91M | 4.56M |
Change in working capital | -9.10200M | -15.21500M | -12.21900M | -4.30400M | -0.60700M |
Stock based compensation | 2.34M | 1.63M | 2.68M | 0.82M | 0.37M |
Other non cash items | 1.18M | 1.29M | -0.23600M | -0.69500M | 0.37M |
Free cash flow | 13.33M | 6.34M | -0.16700M | 6.14M | 8.33M |
Sector: Healthcare Industry: Medical Distribution
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
ZYXI Zynex Inc |
-0.21 1.92% | 10.73 | 25.05 | 19.57 | 1.91 | 6.05 | 2.04 | 15.08 |
MCK McKesson Corporation |
-2.14 0.39% | 543.61 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
COR Cencora Inc. |
-2.68 1.18% | 224.06 | 23.39 | - | - | - | ||
CAH Cardinal Health Inc |
-2.28 2.29% | 97.44 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
HSIC Henry Schein Inc |
1.56 2.19% | 72.76 | 21.82 | 14.33 | 0.76 | 2.63 | 0.92 | 12.98 |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
9655 Maroon Circle, Englewood, CO, United States, 80112
Name | Title | Year Born |
---|---|---|
Mr. Thomas Sandgaard | Founder, Pres, CEO & Chairman | 1959 |
Mr. Daniel J. Moorhead | Chief Financial Officer | 1972 |
Ms. Anna Lucsok | Chief Operating Officer | 1986 |
Ms. Chelle Van Burkleo | VP of Sales | NA |
Mr. Steve Fox | VP Of Sales | NA |
Mr. Dave Anttila | Director of HR | NA |
Mr. Neil Friery | Pres & COO of Zynex Monitoring Solutions, Inc. | NA |
Mr. Joachim Sandgaard | Information Systems Mang. | NA |
Mr. Donald Gregg | VP of Sales and Operations - Monitoring Solutions Division | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).